Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570830 · ClinicalTrials.gov registry record · NA
Retisert and Cataract Surgery in Patients With Severe Uveitis
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT00570830 is a NA study that has completed, run by Duke University. The registered enrollment target is 21 participants.
The verdict
NCT00570830, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
To review chart data at the Duke Eye Center and determined whether a 3-year fluocinolone acetonide sustained drug delivery system (FA) safely suppressed postoperative inflammation when combined with phacoemulsification and posterior chamber intraocular lens implantation (phaco/PCIOL) in eyes with severe uveitis.
Interventions
- DEVICE Retisert (fluocinolone acetonide implant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570830
The ClinicalTrials.gov registry entry for NCT00570830 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Retisert (fluocinolone acetonide implant) is the first listed.
NCT00570830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570830 about?
NCT00570830 is a clinical study titled "Retisert and Cataract Surgery in Patients With Severe Uveitis". To review chart data at the Duke Eye Center and determined whether a 3-year fluocinolone acetonide sustained drug delivery system (FA) safely suppressed postoperative inflammation when combined with phacoemulsification and posterior chamber intraocular lens implantation (phaco/PCIOL) in eyes with se...
What is the current status of trial NCT00570830?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2006-09. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00570830?
The interventions under investigation include: Retisert (fluocinolone acetonide implant) (DEVICE).
Who is sponsoring clinical trial NCT00570830?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.